Eisai Loses Bid For Longer Exclusivity In FDA Delay Fight

Eisai Inc. lost its bid to require the U.S. Food and Drug Administration to extend the market exclusivity periods for two of its drugs when a Washington, D.C., federal judge found...

Already a subscriber? Click here to view full article